Epirium Bio is a biopharmaceutical company that has developed a proprietary platform of orally bioavailable small molecules aimed at treating neuromuscular diseases, such as sarcopenia and spinal muscular atrophy. The company’s research is grounded in a deep understanding of muscle stem cell biology, tissue regeneration, and mitochondrial function, which are critical for rejuvenating muscle. Their lead candidates are designed to harness the body’s natural biological repair mechanisms, targeting an endogenous pathway that is activated following muscle injury. This approach aims to facilitate effective muscle regeneration and slow the progression of various muscle-related diseases.

The company’s innovative mechanism of action involves increasing Prostaglandin E2 (PGE2) levels through the inhibition of 15-PGDH, an enzyme responsible for metabolizing PGE2. This enhancement of PGE2 is essential for promoting skeletal muscle stem-cell function, thereby augmenting muscle regeneration and strength. Epirium Bio's focus on small molecule inhibitors positions it to address significant unmet medical needs across a range of therapeutic areas, with ongoing clinical trials, including a Phase 1 study of EPM-01 for Becker muscular dystrophy, demonstrating their commitment to advancing novel treatments for patients.

United States

Epirium is a clinical-stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy

Epirium

Company Details